Mr. Speaker, I would really look forward to a discussion at committee about just that, hearing from some experts like Joel Lexchin, for example, from York University. That is because the point of fines in this case would be to deter. Companies are making unfathomable amounts of money, so if the fine is not high enough, it is just the cost of doing business. It is much like the cost of doing business is sending their pharmaceutical reps for a cruise after they score a good contract, or down to the south with their families for a couple of weeks. This really happens. It is a gravy train, if one gets a job as a pharmaceutical rep.
Therefore, if a fine is just the cost of doing business and they are still going to make tonnes of money because they have changed one molecule in a drug, then it is not serving the purpose, is it? We will have to ask that at committee.